About Us
About Carna
Management
Our Business
Products & Services
Products
Kinase Proteins and Other Protein Products
Assay Kits
Services
Activity-based Biochemical Screening/Profiling Assay Services
Cell-based Assay Services
Pricing & Technical Inquiry
Drug Discovery
Pipeline
Science
Technology
Partnering
Investors
News
Financial Reports/Presentations
Financial Highlights
IR Schedule
IR Contact
JP
EN
JP
EN
Kinase Inhibitor Discovery
with an untiring quest for future therapeutics
Our Business
Products & Services
Drug Discovery
Latest News
Jan 25, 2023
Investors
Carna Initiates Dosing in the MAD Part of Phase 1 Trial of AS-0871
Jan 05, 2023
Investors
Carna Announces Completion of Dosing in the BA Part of Phase 1 trial of AS-0871
Dec 20, 2022
Investors
Carna Announces Successful Development of New Tablet Formulation of AS-0871
Dec 14, 2022
Investors
Revision of Results Forecast for the Fiscal Year Ending December 31, 2022
Nov 22, 2022
Investors
Notice of Issuance of 20th Series of Stock Acquisition Rights (Third Party Allotment of Floating Strike Warrants)
Nov 07, 2022
Investors
FY2022 Q3 Presentation
Nov 07, 2022
Investors
Consolidated Financial Results for the Third Quarter of the Year Ending December 31, 2022
Aug 05, 2022
Investors
FY2022 Q2 Presentation
About Us
Investors
Investor Contact
Products & Services Contact